Skip to content

Cancer Health Center

Font Size

Late Effects of Treatment for Childhood Cancer (PDQ®): Treatment - Health Professional Information [NCI] - Late Effects of the Reproductive System

continued...

In Europe, survivors of Hodgkin lymphoma treated between the ages 15 years and 40 years and who were not receiving hormonal contraceptives were surveyed for the occurrence of premature ovarian failure. In 460 women, premature ovarian failure was mainly influenced by alkylating chemotherapy use with a linear dose relationship between alkylating chemotherapy and premature ovarian failure occurrence. Premature ovarian failure risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy before age 32 years and at age 32 years or older, cumulative premature ovarian failure risks were 3% and 9%, respectively. If menstruation returned after treatment, cumulative premature ovarian failure risk was independent of age at treatment. Among women who ultimately developed premature ovarian failure, 22% had one or more children after treatment, compared with 41% of women without premature ovarian failure. This report indicates that women with proven fertility after treatment can still face infertility problems at a later stage.[47]

Fertility

Fertility was evaluated among the 6,224 male CCSS participants aged 15 to 44 years who were not surgically sterile. They were less likely to sire a pregnancy than siblings (hazard ratio [HR] 0.56; 95% CI, 0.49–0.63). Among survivors, the HR of siring a pregnancy was decreased by radiation therapy greater than 750 cGy to the testes (HR = 0.12; 95% CI, 0.02–0.64), higher summed alkylating agent dose score or treatment with cyclophosphamide (third tertile - HR = 0.42; 95% CI, 0.31–0.57) or procarbazine (second tertile - HR = 0.48; 95% CI, 0.26–0.87; third tertile – HR = 0.17; 95% CI, 0.07–0.41). The HR of siring a pregnancy was inversely related to the summed alkylating agent dose score (P -value for linear trend = <.001). Those who had a summed alkylating agent dose score of 2 (HR = 0.67; 95% CI, 0.51–0.88; P = .004), 3 (HR = 0.48; 95% CI, 0.36–0.65; P <.001), 4 (HR = 0.34; 95% CI, 0.22–0.52; P <.001), 5 (HR = 0.38; 95% CI, 0.22–0.66; P <.001), or 6 to 11 (HR = 0.16; 95% CI, 0.08–0.32; P <.001) were also less likely to ever sire a pregnancy compared with those who did not receive any alkylating agents. Compared with siblings, the HR for ever siring a pregnancy for survivors who had an alkylating agent dose score of 0 and a hypothalamic/pituitary radiation dose of 0 cGy and a testes radiation dose of 0 cGy was 0.91 (95% CI, 0.73–1.14; P = .41).[48]

1|2|3|4|5|6|7|8|9
Next Article:

Today on WebMD

Colorectal cancer cells
A common one in both men and women.
Lung cancer xray
See it in pictures, plus read the facts.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article